+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating the use of endoscopic surgery as a less invasive alternative to traditional lumbar spine fusion for patients with spinal stenosis and spondylolisthesis. This approach aims to decompress the lumbar spine while preserving its natural function and stability, potentially reducing the need for spinal fusion. The study explores whether endoscopic techniques can lower the rate of more invasive surgical interventions in this population. The study focuses on patients who require spinal decompression surgery and are considered for endoscopic procedures. It observes outcomes related to these minimally destructive surgical methods without introducing experimental drugs or devices. The main goal is to evaluate the rate of surgical reintervention within one year after the initial endoscopic surgery. Participants will be monitored over time to assess if further surgical procedures are needed. Researchers will review medical imaging and clinical data to understand the effectiveness of endoscopic decompression in avoiding fusion surgery. The study involves adults 18 years and older and tracks outcomes related to surgical reintervention during the follow-up period, with participation potentially lasting up to several years.

Age: 18Years +All Genders
13 locations
P

Actively Recruiting

This research investigates GLSI-100 immunotherapy in people with HER2neu positive breast cancer who are at high risk for their cancer returning. It focuses on participants who have completed both neoadjuvant and postoperative adjuvant standard treatments. The study is Phase 3, randomized, double-blinded, and placebo-controlled, involving subjects who are HLA-A*02 positive as well as an open-label group of non-HLA-A*02 positive subjects. The goal is to evaluate the treatments impact on invasive breast cancer-free survival over a median follow-up of 4 years. Participants receive 6 primary immunization injections of GLSI-100 or placebo intradermally once a month for the first 6 months, followed by 5 booster injections spaced 6 months apart, totaling 11 injections over 3 years. There are three groups one receiving placebo 0.9% normal saline, one receiving GLSI-100 immunotherapy in HLA-A*02 positive subjects, and an open-label arm for non-HLA-A*02 positive subjects receiving GLSI-100 under the same schedule. During the study, participants undergo regular monitoring and assessments including invasive disease-free survival, distant disease-free survival, overall survival, and quality of life questionnaires at baseline and up to 36 months. Researchers track safety and treatment effects over a median 4-year follow-up. The study continues until December 2031, aiming to provide comprehensive data on long-term outcomes and quality of life for participants receiving these treatments.

Age: 18Years - 100YearsAll GendersPhase 3
179 locations
P

Actively Recruiting

Squamous cell carcinoma of the anus is a rare but increasingly common cancer, often linked to human papillomavirus HPV. For early-stage tumors, combined radiotherapy and chemotherapy with 5FU and mitomycin-C provide good outcomes, but advanced tumors have a poor prognosis with a high relapse rate. Researchers are studying a new approach combining induction chemotherapy with docetaxel, cisplatin, and 5FU mDCF followed by standard chemoradiotherapy to improve treatment results for locally advanced anal cancer T3-4 or N1. This is a randomized phase 3 trial comparing this new strategy to the current standard treatment. The study includes two groups one receives the usual chemoradiotherapy, which involves 33 radiotherapy sessions over 6.5 weeks combined with mitomycin-C and capecitabine chemotherapy taken on radiotherapy days. The other group starts with 4 cycles of mDCF chemotherapy given every two weeks before receiving the same chemoradiotherapy as the control group. Radiotherapy uses intensity-modulated external irradiation with a targeted boost to the tumor and involved lymph nodes. Participants will be followed after treatment with check-ups at 8 weeks, then every 4 months for two years, and every 6 months in the third year. Follow-up includes clinical exams and imaging scans CT and MRI. The main measure of success is disease-related event-free survival two years after treatment. Other outcomes include overall survival, colostomy-free survival, treatment side effects, tumor response, and quality of life. The total study duration for each participant may extend over several years including this follow-up period.

Age: 18Years +All GendersPhase 3
114 locations
R

Actively Recruiting

Researchers are conducting a French national observational study to evaluate patients with HER2-negative early breast cancer who are treated with olaparib. The study aims to understand how many patients complete the full adjuvant olaparib treatment in a real-world setting. This study observes patients receiving olaparib as part of their standard care without assigning treatments. Participants are those diagnosed with HER2-negative early breast cancer and starting adjuvant olaparib based on their physicians decision. The study does not provide or assign treatments but follows patients who are prescribed olaparib in routine clinical practice. There are no comparison groups or placebo treatments in this observational study. During the study, researchers will monitor patients for up to 18 months to measure the proportion who complete the full olaparib treatment course. They will also collect information on BRCA mutation characteristics, medical history, and the timing of treatment discontinuation. Participants will be observed through routine care without additional interventions, allowing researchers to assess real-world treatment adherence and outcomes.

Age: 18Years +All Genders
58 locations
E

Actively Recruiting

Researchers are evaluating whether certain women with early-stage, low-risk hormone receptor-positive and HER2-negative breast cancer can safely skip hormone therapy after surgery and possibly radiation therapy. This study focuses on postmenopausal women aged 60 and older with small tumors that have a very low risk of recurrence. It aims to compare outcomes for those who avoid hormone treatment with others who received standard hormone therapy in a different study, while also assessing their risk of cancer return, cardiovascular and bone health, and quality of life. Participants will not receive any hormone therapy such as tamoxifen or aromatase inhibitors during the study. All participants must have had surgery to remove the tumor, and if breast-conserving surgery was performed, they should have received or be scheduled for radiotherapy within three months after surgery. No chemotherapy will be given or planned. The study will enroll participants for two years, followed by up to five years of monitoring after the last person joins to observe long-term cancer recurrence and other health outcomes. During the study, participants will attend scheduled visits for medical evaluations, laboratory tests, and complete quality of life and mood questionnaires at baseline, 6 months, 1 year, and annually thereafter until five years after the last participant is enrolled. Researchers will monitor cancer recurrence rates, bone and cardiovascular events, and overall survival. This comprehensive follow-up aims to understand the effects of avoiding hormone therapy on both cancer outcomes and participants wellbeing over time.

Age: 60Years +FEMALEPhase 2
41 locations